Furthermore, clinical trial NCT04995003 aimed to determine the safety and side effects of administering HER2-CAR-T cells in combination with immune checkpoint inhibitors (pembrolizumab or nivolumab) and their potential efficacy in patients with sarcoma. The gene discussed is ERBB2; the disease is sarcoma.